The foreign drug manufacturer, Lupin Ltd., has decided to recall 9,210
bottles of the drug called Suprax. The recalled bottles of Suprax failed
to pass various purity tests performed in the United States, according
to the Food and Drug Administration. Although the defective products are
alleged to be harmless by the manufacturer, purity tests are performed
for the reason of identifying and removing potentially dangerous drugs
from the market before anyone suffers injury. For this reason, New York
consumers may wish to avoid consuming pills found in recalled bottles
of Suprax -- for safety purposes.
Last year, Lupin Ltd. initiated a recall that affected even more bottles
of its drugs when it recalled almost 65,000 bottles for discoloration
problems. Other recalls affecting pharmaceuticals made by other manufacturers
were also initiated this year. Sun Pharmaceutical Industries Ltd., Dr.
Reddy's Laboratories Ltd. and Ranbaxy Laboratories have all been affected
by recalls in this calendar year.
The recall of Suprax comes as the FDA applies more scrutiny to the purity
and quality of pharmaceutical medications made in India, where Lupin Ltd.
is located. At this time, four out of every 10 of the generic medicines
and over-the-counter treatments sold to United States consumers were manufactured
in India. Considering that these drugs are distributed to consumers across
the country, it is commendable that the FDA is applying more scrutiny
to Indian manufacturers.
Doctors administer Suprax to their patients in order to treat and prevent
bacterial infections. Patients who are battling infections are highly
susceptible to impurities that can be found in defective drugs, and it
is important that drugs ingested by these patients -- including Suprax
-- be subjected to the highest standards. Any New York resident who suspects
that he or she has been hurt after taking dangerous drugs may wish to
investigate the strength of pursuing a products liability claim under the law.
Source: Reuters, "Lupin pulls over 9,000 bottles of anti-infective Suprax
from U.S. -FDA" , April 15, 2014